OSSIO Inc. has strayed a long way from its home base.

The orthopedic implant developer celebrated the grand opening of its new U.S. headquarters earlier this week in Palmetto, Fla., with a ceremonial welcome from the Sunshine State’s lieutenant governor and more than 50 other business, government, and healthcare leaders.

Founded in Israel in 2014, OSSIO selected Florida to expand its operations due to the state’s combination of technical talent and economic incentives to support sustainable growth, OSSIO CEO Brian Verrier said. The company expects to create about 100 new jobs in Palmetto over the next five years, with a focus on production, commercial, and administrative staff. Initial job recruiting began in January.

“OSSIO’s expansion is a landmark moment for the Florida-Israel innovation corridor,” Florida-Israel Business Accelerator (FIBA) Co-Executive Director Rakefet Bachur-Phillips said. “Their growth in Florida is a win for our economy and a victory for patients everywhere. OSSIO is a prime example of the ‘Startup Nation’ spirit, and we are proud to support them as they scale their life-changing technology.”

Florida Lt. Gov. Jay Collins addressed an audience of approximately 150 people in front of OSSIO’s new 30,000 square foot facility, which houses a state-of-the-art product manufacturing plant and a best-in-class surgeon training center.

“Florida continues to be a destination of choice for innovative companies that are transforming the future of healthcare,” Collins stated. “OSSIO’s decision to establish its U.S. headquarters here in Palmetto reflects Florida’s strong workforce, pro-growth environment and commitment to supporting advanced manufacturing and medical innovation. This investment will create high-quality jobs, strengthen our life sciences sector and position Florida at the forefront of next-generation orthopedic technology.”

“We couldn’t feel more welcome in Florida,” Verrier beamed after the ribbon cutting, which involved Collins, SelectFlorida President Mark Swanson, BioFlorida President/CEO Mark Glickman, Bachur-Phillips, and Florida-Israel Business Accelerator (FIBA) Co-Executive Director Pam Miniati, among others. “Our future in the Sunshine State is clearly bright. We’re very much looking forward to driving the company’s ambitious growth plans from our new U.S. headquarters, which promises to boost the local economy even more by bringing hundreds of surgeons to the Gulf Coast each year for training on our medical technology for orthopedic surgery.”

“We’re thrilled to welcome OSSIO to Florida and to the BioFlorida community. OSSIO represents exactly the kind of innovative, patient- and caregiver-focused company that continues to strengthen Florida’s position as a national powerhouse in medical technology,” BioFlorida’s Glickman added. “The company’s decision to locate advanced manufacturing and surgeon training here speaks volumes about the depth of our talent, the strength of our life sciences ecosystem and Florida’s commitment to supporting companies that are truly changing lives through innovation.”

Based on Intelligent Bone Regeneration Technology, OSSIOfiber implants combine mechanical strength and natural healing in a bio-integrative, metal-free design. Their proprietary polymeric mineral fiber matrix enables rapid bone in-growth, regeneration and replacement—a new way for orthopedic surgeons to restore their patients’ stability and mobility while leaving nothing permanent behind.

OSSIOfiber implants represent the first credible alternative to metal, absorbable and allograft fixation devices. The most significant advance in orthopedic fixation technology in more than a century, this medical technology can potentially address an increasingly wide array of surgical applications due to the proprietary “know-how” to manufacture limitless implant platforms. The company intends to continue developing additional applications for OSSIOfiber implants in all major segments of orthopedics.

OSSIOfiber implants utilize existing reimbursement codes and surgical techniques. Their uptake continues to grow because of strong patient and surgeon preference to avoid the concerns and complications of metal fixation implants, according to the company. Through December 2025, more than 65,000 OSSIOfiber implants have been used to treat U.S. orthopedic patients

OSSIO Inc is an orthopedic medical technology company transforming the surgical experience for patients, physicians, providers, and payors. It strives to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO conducts product development in Caesarea, Israel, and commercial operations in Palmetto, Fla., and Woburn, Mass.